Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Intravenous Immunoglobulin (IVIG) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Published by Transparency Market Research Product code 640996
Published Content info 155 Pages
Delivery time: 1-2 business days
Price
Back to Top
Intravenous Immunoglobulin (IVIG) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024
Published: April 23, 2018 Content info: 155 Pages
Description

Intravenous Immunoglobulin (IVIG) Market: Scope and Methodology

This report on the global intravenous immunoglobulin (IVIG) market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global intravenous immunoglobulin (IVIG) market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the intravenous immunoglobulin (IVIG) market such as shift from intravenous to subcutaneous infusion of immunoglobulin. The key market indicators influencing global intravenous immunoglobulin (IVIG) market taken into consideration include prevalence of immunological disorders, global blood and plasma yield and geriatric population. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global intravenous immunoglobulin (IVIG) market. The report also highlights key events of the global intravenous immunoglobulin industry. A value chain analysis along with list of major players, hospitals and distributors is also included in the report.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2017 to 2024 are provided for all the segments, considering 2016 as the base year. The year on year growth of global intravenous immunoglobulin (IVIG) market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and growing number of acute and chronic patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Intravenous Immunoglobulin (IVIG) Market: Segmentation

Based on indication, the global intravenous immunoglobulin (IVIG) market has been segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. Based on end-user, the market has been segmented into hospitals, clinics, and home care. Hospitals segment is expected to remain dominant during the forecast period. However, home care segment is expected to grow at a higher CAGR than others.

Geographically, the global intravenous immunoglobulin (IVIG) market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.

Intravenous Immunoglobulin (IVIG) Market: Competitive Landscape

The report also profiles major players in the intravenous immunoglobulin (IVIG) market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the intravenous immunoglobulin (IVIG) market is provided in the report. The report also includes a competition matrix that provides insights into recent developments and activities done by the major market players. Key companies profiled in the report include Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V.

The global intravenous immunoglobulin (IVIG) market has been segmented as follows:

Global Intravenous immunoglobulin (IVIG) Market, by Indication

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Primary Humoral Immunodeficiency
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Guillain-Barre Syndrome
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy (MMN)
  • Kawasaki Disease
  • Hypogammaglobulinemia
  • Chronic Lymphocytic Leukemia
  • Others

Global Intravenous immunoglobulin (IVIG) Market, by End-user

  • Hospitals
  • Clinics
  • Home Care

Global Intravenous immunoglobulin (IVIG) Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa
Table of Contents

Table of Contents

Section 1: Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

Section 2: Assumptions and Research Methodology

  • 2.1. Assumptions
  • 2.2. Research Methodology

Section 3: Executive Summary

  • 3.1. Global Intravenous Immunoglobulin (IVIG): Market Snapshot
  • 3.2. Market Share Analysis by Region, 2015
  • 3.3. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Map

Section 4: Market Overview

  • 4.1. Indication Overview
  • 4.2. Global Intravenous Immunoglobulin (IVIG) Market: Key Industry Developments
  • 4.3. Global Intravenous Immunoglobulin (IVIG) Market: Market Indicators

Section 5: Market Dynamics

  • 5.1. Drivers and Restraints Snapshot Analysis
  • 5.2. Drivers
    • 5.2.1. Rise in prevalence of autoimmune disorders
    • 5.2.2. Increase in global geriatric population
    • 5.2.3. Growing usage in off-label indications
    • 5.2.4. Improved technology for production and purification methods
    • 5.2.5. Favorable government initiatives and approvals
    • 5.2.6. Increase in health care spending & improving health care infrastructure
    • 5.2.7. Rise in incidence of hematological, neurological disorders
  • 5.3. Restraints
    • 5.3.1. High cost of treatment
    • 5.3.2. Chronic side effects
    • 5.3.3. Supply demand gaps
    • 5.3.4. Alternate therapies such as subcutaneous infusion IG (SCIG) and recombinant Indications
  • 5.4. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Analysis
  • 5.5. Opportunities
    • 5.5.1. Application in newer indications
    • 5.5.2. Increasing global plasma yield to offer significant opportunities to new entrants
  • 5.6. Key Trends
  • 5.7. Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014-2024
  • 5.8. Value Chain Analysis
  • 5.9. Intravenous Immunoglobulin (IVIG) Market Outlook

Section 6: Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication

  • 6.1. Key Findings
  • 6.2. Introduction
  • 6.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication
  • 6.4. Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
    • 6.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 6.4.2. Primary Humoral Immunodeficiency
    • 6.4.3. Idiopathic Thrombocytopenic Purpura (ITP)
    • 6.4.4. Guillain-Barre Syndrome
    • 6.4.5. Myasthenia Gravis
    • 6.4.6. Multifocal Motor Neuropathy (MMN)
    • 6.4.7. Kawasaki Disease
    • 6.4.8. Hypogammaglobulinemia
    • 6.4.9. Chronic Lymphocytic Leukemia
    • 6.4.10. Others
  • 6.5. Market Attractiveness Analysis, by Indication
  • 6.6. Key Trends

Section 7: Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user

  • 7.1. Key Findings
  • 7.2. Introduction
  • 7.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user
  • 7.4. Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
    • 7.4.1. Hospitals
    • 7.4.2. Clinics
    • 7.4.3. Home Care
  • 7.5. Market Attractiveness Analysis, by End-user
  • 7.6. Key Trends

Section 8: Intravenous Immunoglobulin (IVIG) Market Analysis, by Region

  • 8.1. Global Intravenous Immunoglobulin (IVIG) Market Snapshot, by Country
  • 8.2. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region
  • 8.3. Intravenous Immunoglobulin (IVIG) Market Forecast, by Region
  • 8.4. Market Attractiveness Analysis, by Region

Section 9: North America Intravenous Immunoglobulin (IVIG) Market Analysis

  • 9.1. Key Findings
  • 9.2. Market Overview
  • 9.3. Market Analysis, by Indication
    • 9.3.1. Market Value Share Analysis, by Indication
    • 9.3.2. Market Size (US$ Mn) Forecast, by Indication
      • 9.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      • 9.3.2.2. Primary Humoral Immunodeficiency
      • 9.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
      • 9.3.2.4. Guillain-Barre Syndrome
      • 9.3.2.5. Myasthenia Gravis
      • 9.3.2.6. Multifocal Motor Neuropathy (MMN)
      • 9.3.2.7. Kawasaki Disease
      • 9.3.2.8. Hypogammaglobulinemia
      • 9.3.2.9. Chronic Lymphocytic Leukemia
      • 9.3.2.10. Others
  • 9.4. Market Analysis, by End-user
    • 9.4.1. Market Value Share Analysis, by End-user
    • 9.4.2. Market Size (US$ Mn) Forecast, by End-user
      • 9.4.2.1. Hospitals
      • 9.4.2.2. Clinics
      • 9.4.2.3. Home Care
  • 9.5. Market Analysis, by Country
    • 9.5.1. Market Value Share Analysis, by Country
    • 9.5.2. Market Size (US$ Mn) Forecast, by Country, 2016-2024
      • 9.5.2.1. U.S.
      • 9.5.2.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. by Indication
    • 9.6.2. by End-user
    • 9.6.3. by Country

Section 10: Europe Intravenous Immunoglobulin (IVIG) Market Analysis

  • 10.1. Key Findings
  • 10.2. Market Overview
  • 10.3. Market Analysis, by Indication
    • 10.3.1. Market Value Share Analysis, by Indication
    • 10.3.2. Market Size (US$ Mn) Forecast, by Indication
      • 10.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      • 10.3.2.2. Primary Humoral Immunodeficiency
      • 10.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
      • 10.3.2.4. Guillain-Barre Syndrome
      • 10.3.2.5. Myasthenia Gravis
      • 10.3.2.6. Multifocal Motor Neuropathy (MMN)
      • 10.3.2.7. Kawasaki Disease
      • 10.3.2.8. Hypogammaglobulinemia
      • 10.3.2.9. Chronic Lymphocytic Leukemia
      • 10.3.2.10. Others
  • 10.4. Market Analysis, by End-user
    • 10.4.1. Market Value Share Analysis, by End-user
    • 10.4.2. Market Size (US$ Mn) Forecast, by End-user
      • 10.4.2.1. Hospitals
      • 10.4.2.2. Clinics
      • 10.4.2.3. Home Care
  • 10.5. Market Analysis, by Country
    • 10.5.1. Market Value Share Analysis, by Country
    • 10.5.2. Market Size (US$ Mn) Forecast, by Country, 2016-2024
      • 10.5.2.1. U.K.
      • 10.5.2.2. Germany
      • 10.5.2.3. France
      • 10.5.2.4. Spain
      • 10.5.2.5. Italy
      • 10.5.2.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. by Indication
    • 10.6.2. by End-user
    • 10.6.3. by Country

Section 11: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis

  • 11.1. Key Findings
  • 11.2. Market Overview
  • 11.3. Market Analysis, by Indication
    • 11.3.1. Market Value Share Analysis, by Indication
    • 11.3.2. Market Size (US$ Mn) Forecast, by Indication
      • 11.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      • 11.3.2.2. Primary Humoral Immunodeficiency
      • 11.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
      • 11.3.2.4. Guillain-Barre Syndrome
      • 11.3.2.5. Myasthenia Gravis
      • 11.3.2.6. Multifocal Motor Neuropathy (MMN)
      • 11.3.2.7. Kawasaki Disease
      • 11.3.2.8. Hypogammaglobulinemia
      • 11.3.2.9. Chronic Lymphocytic Leukemia
      • 11.3.2.10. Others
  • 11.4. Market Analysis, by End-user
    • 11.4.1. Market Value Share Analysis, by End-user
    • 11.4.2. Market Size (US$ Mn) Forecast, by End-user
      • 11.4.2.1. Hospitals
      • 11.4.2.2. Clinics
      • 11.4.2.3. Home Care
  • 11.5. Market Analysis, by Country
    • 11.5.1. Market Value Share Analysis, by Country
    • 11.5.2. Market Size (US$ Mn) Forecast, by Country, 2016-2024
      • 11.5.2.1. China
      • 11.5.2.2. Japan
      • 11.5.2.3. Australia
      • 11.5.2.4. India
      • 11.5.2.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. by Indication
    • 11.6.2. by End-user
    • 11.6.3. by Country

Section 12: Latin America Intravenous Immunoglobulin (IVIG) Market Analysis

  • 12.1. Key Findings
  • 12.2. Market Overview
  • 12.3. Market Analysis, by Indication
    • 12.3.1. Market Value Share Analysis, by Indication
    • 12.3.2. Market Size (US$ Mn) Forecast, by Indication
      • 12.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      • 12.3.2.2. Primary Humoral Immunodeficiency
      • 12.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
      • 12.3.2.4. Guillain-Barre Syndrome
      • 12.3.2.5. Myasthenia Gravis
      • 12.3.2.6. Multifocal Motor Neuropathy (MMN)
      • 12.3.2.7. Kawasaki Disease
      • 12.3.2.8. Hypogammaglobulinemia
      • 12.3.2.9. Chronic Lymphocytic Leukemia
      • 12.3.2.10. Others
  • 12.4. Market Analysis, by End-user
    • 12.4.1. Market Value Share Analysis, by End-user
    • 12.4.2. Market Size (US$ Mn) Forecast, by End-user
      • 12.4.2.1. Hospitals
      • 12.4.2.2. Clinics
      • 12.4.2.3. Home Care
  • 12.5. Market Analysis, by Country
    • 12.5.1. Market Value Share Analysis, by Country
    • 12.5.2. Market Size (US$ Mn) Forecast, by Country, 2016-2024
      • 12.5.2.1. Brazil
      • 12.5.2.2. Mexico
      • 12.5.2.3. Rest of LATAM
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. by Indication
    • 12.6.2. by End-user
    • 12.6.3. by Country

Section 13: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Overview
  • 13.3. Market Analysis, by Indication
    • 13.3.1. Market Value Share Analysis, by Indication
    • 13.3.2. Market Size (US$ Mn) Forecast, by Indication
      • 13.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      • 13.3.2.2. Primary Humoral Immunodeficiency
      • 13.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
      • 13.3.2.4. Guillain-Barre Syndrome
      • 13.3.2.5. Myasthenia Gravis
      • 13.3.2.6. Multifocal Motor Neuropathy (MMN)
      • 13.3.2.7. Kawasaki Disease
      • 13.3.2.8. Hypogammaglobulinemia
      • 13.3.2.9. Chronic Lymphocytic Leukemia
      • 13.3.2.10. Others
  • 13.4. Market Analysis, by End-user
    • 13.4.1. Market Value Share Analysis, by End-user
    • 13.4.2. Market Size (US$ Mn) Forecast, by End-user
      • 13.4.2.1. Hospitals
      • 13.4.2.2. Clinics
      • 13.4.2.3. Home Care
  • 13.5. Market Analysis, by Country
    • 13.5.1. Market Value Share Analysis, by Country
    • 13.5.2. Market Size (US$ Mn) Forecast, by Country, 2016-2024
      • 13.5.2.1. South Africa
      • 13.5.2.2. Saudi Arabia
      • 13.5.2.3. Rest of MEA
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. by Indication
    • 13.6.2. by End-user
    • 13.6.3. by Country

Section 14: Company Profiles

  • 14.1. Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2015)
  • 14.2. Competition Matrix
  • 14.3. Company Profiles
    • 14.3.1. Baxalta Incorporated
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Financial Overview
      • 14.3.1.3. Product Portfolio
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Biotest AG
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Financial Overview
      • 14.3.2.3. Product Portfolio
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. China Biologic Products, Inc.
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Financial Overview
      • 14.3.3.3. Product Portfolio
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. CSL Behring LLC
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Financial Overview
      • 14.3.4.3. Product Portfolio
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Grifols S.A.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Financial Overview
      • 14.3.5.3. Product Portfolio
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Kedrion S.p.A.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Financial Overview
      • 14.3.6.3. Product Portfolio
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. LFB Biomedicaments S.A.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Financial Overview
      • 14.3.7.3. Product Portfolio
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Octapharma AG
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Financial Overview
      • 14.3.8.3. Product Portfolio
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Sanquin Plasma Products B.V.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Financial Overview
      • 14.3.9.3. Product Portfolio
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview

List of Tables

  • Table 01: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016-2024
  • Table 02: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016-2024
  • Table 03: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Region, 2016-2024
  • Table 04: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016-2024
  • Table 05: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016-2024
  • Table 06: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • Table 07: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016-2024
  • Table 08: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016-2024
  • Table 09: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • Table 10: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016-2024
  • Table 11: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016-2024
  • Table 12: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • Table 13: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2014-2024
  • Table 14: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2014-2024
  • Table 15: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2014-2024
  • Table 16: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication Type, 2014-2024
  • Table 17: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2014-2024
  • Table 18: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2014-2024

List of Figures

  • Figure 01: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014-2024
  • Figure 02: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 03: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue, US$ Mn, 2014-2024
  • Figure 04: Global Primary Humoral Immunodeficiency Market Revenue, US$ Mn, 2014-2024
  • Figure 05: Global Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, US$ Mn, 2014-2024
  • Figure 06: Global Guillain-Barre Syndrome Market Revenue, US$ Mn, 2014-2024
  • Figure 07: Global Myasthenia Gravis Market Revenue, US$ Mn, 2014-2024
  • Figure 08: Global Multifocal Motor Neuropathy (MMN) Market Revenue, US$ Mn, 2014-2024
  • Figure 09: Global Kawasaki Disease Market Revenue, US$ Mn, 2014-2024
  • Figure 10: Global Hypogammaglobulinemia Market Revenue, US$ Mn, 2014-2024
  • Figure 11: Global Chronic Lymphocytic Leukemia Market Revenue, US$ Mn, 2014-2024
  • Figure 12: Global Other Indications Market Revenue, US$ Mn, 2014-2024
  • Figure 13: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Indication
  • Figure 14: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user, 2016 and 2024
  • Figure 15: Global Hospitals Market Revenue, US$ Mn,
  • Figure 16: Global Clinics Market Revenue, US$ Mn,
  • Figure 17: Global home care Market Revenue, US$ Mn, 2014-2024
  • Figure 18: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by End-user
  • Figure 19: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region, 2016 and 2024
  • Figure 20: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Region
  • Figure 21: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 22: North America Market Attractiveness Analysis, by Country
  • Figure 23: North America Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 24: North America Market Value Share Analysis, by End-user, 2016 and 2024
  • Figure 25: North America Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 26: North America Market Attractiveness Analysis, by Indication
  • Figure 27: North America Market Attractiveness Analysis, by End-user
  • Figure 28: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016-2024
  • Figure 29: Europe Market Attractiveness Analysis, by Country
  • Figure 30: Europe Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 31: Europe Market Value Share Analysis, by End-user, 2016 and 2024
  • Figure 32: Europe Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 33: Europe Market Attractiveness Analysis, by Indication
  • Figure 34: Europe Market Attractiveness Analysis, by End-user
  • Figure 35: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014-2024
  • Figure 36: Asia Pacific Market Attractiveness Analysis, by Country
  • Figure 37: Asia Pacific Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 38: Asia Pacific Market Value Share Analysis, by End-user, 2016 and 2024
  • Figure 39: Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 40: Asia Pacific Market Attractiveness Analysis, by Indication
  • Figure 41: Asia Pacific Market Attractiveness Analysis, by End-user
  • Figure 42: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014-2024
  • Figure 43: Latin America Market Attractiveness Analysis, by Country
  • Figure 44: Latin America Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 45: Latin America Market Value Share Analysis, by End-user, 2016 and 2024
  • Figure 46: Latin America Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 47: Latin America Market Attractiveness Analysis, by Indication
  • Figure 48: Latin America Market Attractiveness Analysis, by End-user
  • Figure 49: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014-2024
  • Figure 50: Middle East & Africa Market Attractiveness Analysis, by Country
  • Figure 51: Middle East & Africa Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 52: Middle East & Africa Market Value Share Analysis, by End-user, 2016 and 2024
  • Figure 53: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 54: Middle East & Africa Market Attractiveness Analysis, by Indication
  • Figure 55: Middle East & Africa Market Attractiveness Analysis, by End-user
  • Figure 56: Global Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2015)
Back to Top